Artiva remains on track to share initial clinical response data and conduct U.S. Food and Drug Administration (FDA) ...

FDA Alignment -- BioAtla ( BCAB 4.08%) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints ...

We might finally be able to spot osteoarthritis early… and bring it to a halt. First, we need to agree on what it actually is ...

Texas A&M scientists have unlocked new potential for astatine-211, a rare and short-lived element, as a highly precise cancer-fighting isotope. Its alpha emissions destroy tumor cells while sparing ...

Recent research has investigated the potential health benefits of vitamin D, and the role it may play in protecting against certain health conditions. One study found that vitamin ...

Scientists developed a drug that destroys a cancer protein rather than blocking it, cutting pancreatic tumor growth by half ...

Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary ...

The initial public offering (IPO) of Emmvee Photovoltaic Power Ltd, a leading manufacturer of solar photovoltaic (PV) modules ...

Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204's exceptional efficacy across multiple human cancer cell ...

In about six weeks, Massachusetts and all 50 states expect to learn whether they’ll receive some of a $50 billion federal ...

Over 100 patients treated with AlloNK across autoimmune and oncology indications Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast Track Designation for AlloNK®, ...

The FDA has cleared a phase 3 trial for lacutamab in CTCL, following promising phase 2 results showing durable activity and safety. TELLOMAK 3 will assess progression-free survival with two cohorts: ...